The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Protein Kinase C: Structure, Function, and Regulation
Newton, A. C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28495 · Cited by 1,655
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
Review of epidermal growth factor receptor biology
Herbst, R. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.041 · Cited by 1,390
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Biology of Gastrointestinal Stromal Tumors
Corless, C. L., Fletcher, J. A., & Heinrich, M. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.140 · Cited by 1,224
Protein kinase C isoenzymes: divergence in signal transduction?
Hug, H., & Sarre, T. F. (1993) · Biochemical Journal · doi:10.1042/bj2910329 · Cited by 1,220
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Self-citationShou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 685
Mechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Self-citationErber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V, & Kitchen, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1936 · Cited by 528
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
United States Food and Drug Administration Drug Approval Summary
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0564 · Cited by 503
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
Self-citationDebiec-Rychter, M., Cools, J., Dumez, H., Sciot, R., Stul, M., Mentens, N., Vranckx, H., Wasag, B., Prenen, H., Roesel, J., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.020 · Cited by 494
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen, M. H., Williams, G., Johnson, J. R., Duan, J. Z., Gobburu, J. V. S., Rahman, A., Benson, K. A., Leighton, J. K., Kim, S. K., Wood, R., et al. (2002) · PubMed · Cited by 462
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 448
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras, K., Rubin, K., Sjöblom, T., Buchdunger, E., Sjöquist, M., Heldin, C., & Östman, A. (2002) · PubMed · Cited by 433
Cohen, M. H., Farrell, A., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0255 · Cited by 426
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Signal transduction and oncogenesis by ErbB/HER receptors
Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389
The Albert Lasker Medical Awards. The family of protein kinase C for signal transduction
Nishizuka, Y. (1989) · JAMA · doi:10.1001/jama.262.13.1826 · Cited by 389
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., & Bukowski, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba4510 · Cited by 348
p38 MAP kinase: a convergence point in cancer therapy
Olson, J. M., & Hallahan, A. R. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.007 · Cited by 335
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
Östman, A. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.002 · Cited by 326
Molecular genetics of multiple endocrine neoplasia types 1 and 2
Marx, S. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1610 · Cited by 322
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
She, Q., Solit, D. B., Basso, A., & Moasser, M. M. (2003) · PubMed · Cited by 287
Berlin, L. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.2.9456928 · Cited by 272
Schueneman, A. J., Himmelfarb, E. A., Geng, L., Tan, J., Donnelly, E. F., Mendel, D. B., McMahon, G., & Hallahan, D. E. (2003) · PubMed · Cited by 259
Metronomic scheduling: the future of chemotherapy?
Gasparini, G. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00587-3 · Cited by 251
Abrams, T. J., Murray, L. J., Pesenti, E. A., et al. (2003) · PubMed · Cited by 251
Raf kinase as a target for anticancer therapeutics
Sridhar, S. S., Hedley, D., & Siu, L. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0297 · Cited by 245
Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244
Johnson, J. R., Cohen, M., Sridhara, R., Chen, Y.-F., Williams, G. M., Duan, J., Gobburu, J., Booth, B., Benson, K., Leighton, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0790 · Cited by 219
Rapamycin Resistance Tied to Defective Regulation of p27 Kip1
Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., & Marks, A. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6744 · Cited by 210
Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice
Stewart, C. F., Leggas, M., Schuetz, J. D., Panetta, J. C., Cheshire, P. J., Peterson, J., Daw, N., Jenkins, J. J., Gilbertson, R., Germain, G. S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0096 · Cited by 203
Ichihara, M. (2004) · Cancer Letters · doi:10.1016/s0304-3835(03)00456-7 · Cited by 197
Gefitinib reverses breast cancer resistance protein–mediated drug resistance
Yanase, K., Tsukahara, S., Asada, S., Ishikawa, E., Imai, Y., & Sugimoto, Y. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1119.3.9 · Cited by 196
Huber, P. E., Bischof, M., Jenne, J., Heiland, S., Peschke, P., Saffrich, R., Gröne, H.-J., Debus, J., Lipson, K. E., & Abdollahi, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1668 · Cited by 185
Wu, H., Chang, D.-K., & Huang, C.-T. (2006) · Cited by 185
The isoform-specific regulation of apoptosis by protein kinase C
Gutcher, I., Webb, P. R., & Anderson, N. G. (2003) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-003-2281-y · Cited by 183
Kitazaki, T., Oka, M., Nakamura, Y., Tsurutani, J., Doi, S., Yasunaga, M., Takemura, M., Yabuuchi, H., Soda, H., & Kohno, S. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.03.035 · Cited by 182
Protein kinase C inhibitors as novel anticancer drugs
Jirousek, M. R., & Goekjian, P. G. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2117 · Cited by 182
Nakamura, Y., Oka, M., Soda, H., Shiozawa, K., Yoshikawa, M., Itoh, A., Ikegami, Y., Tsurutani, J., Nakatomi, K., Kitazaki, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-2417 · Cited by 177
Gee, J. M. W., Harper, M. E., Hutcheson, I. R., Madden, T. A., Barrow, D., Knowlden, J. M., McClelland, R. A., Jordan, N., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2003-0705 · Cited by 170
Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics
R BOARD, & Jayson, G. C. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.03.004 · Cited by 157
Osusky, K. L., Hallahan, D. E., Fu, A., Ye, F., Shyr, Y., & Geng, L. (2004) · Angiogenesis · doi:10.1007/s10456-004-3149-y · Cited by 155
Kumar, R., Mandal, M., Lipton, A., Harvey, H. A., & Thompson, C. B. (1996) · PubMed · Cited by 144
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Nahta, R., Hortobágyi, G. N., & Esteva, F. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-1-5 · Cited by 135
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS
Tibes, R., Trent, J. C., & Kurzrock, R. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100124 · Cited by 133
Endothelial cell survival and apoptosis in the tumor vasculature
Liu, W., Ahmad, S. A., Reinmuth, N., Shaheen, R. M., Jung, Y. D., Fan, F., & Ellis, L. M. (2000) · APOPTOSIS · doi:10.1023/a:1009679307513 · Cited by 132
The role of EGFR inhibitors in nonsmall cell lung cancer
Ciardiello, F., Vita, F. D., Orditura, M., & Tortora, G. (2004) · Current Opinion in Oncology · doi:10.1097/00001622-200403000-00008 · Cited by 122
Croom, K. F., & Perry, C. M. (2003) · Drugs · doi:10.2165/00003495-200363050-00005 · Cited by 120
Punt, C. J. A., Boni, J. P., Bruntsch, U., Peters, M. E. W. J., & Thielert, C. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg248 · Cited by 117
Mammalian Target of Rapamycin Inhibition
Dutcher, J. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050008 · Cited by 114
Protein kinase C: a target for anticancer drugs?
MacKay, H. J., & Twelves, C. J. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100389 · Cited by 104
Johnson, J. R., Bross, P. F., Cohen, M. H., et al. (2003) · PubMed · Cited by 101
Cetuximab: In the Treatment of Metastatic Colorectal Cancer
Reynolds, N. A., & Wagstaff, A. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00007 · Cited by 100
Lin, M. I., & Sessa, W. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.003 · Cited by 81
de Aguirre, Boya, P., Bellet, D. H., Faivre, S. J., Troalen, F., Bénard, J., Saulnier, P., Hopkins-Donaldson, S., Zangemeister‐Wittke, U., Kroemer, G., et al. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045781.46314.e2 · Cited by 78
Self-citationModulation of protein kinase C in antitumor treatment
Hofmann, J. (2008) · Springer eBooks · doi:10.1007/bfb0117491 · Cited by 76
Biology of Gastrointestinal Stromal Tumors: KIT Mutations and Beyond
Duensing, A. U., Heinrich, M. C., Fletcher, C. D. �., & Fletcher, J. A. (2004) · Cancer Investigation · doi:10.1081/cnv-120027585 · Cited by 76
Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)
Argiris, A. E., Wang, C.-X., Whalen, S. G., & DiGiovanna, M. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1060-02 · Cited by 73
Herbst, R. S., Takeuchi, H., & Teicher, B. A. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050773 · Cited by 67
Monnerat, C., Henriksson, R., Chevalier, T. L., Novello, S., Berthaud, P., Faivre, S. J., & Raymond, É. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh052 · Cited by 66
Self-citationBaselga, J. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.903 · Cited by 63
Oncogenic protein tyrosine kinases
Naoe, T., & Kiyoi, H. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4274-x · Cited by 61
Flaherty, K. T., Redlinger, M., Schuchter, L. M., Lathia, C. D., Weber, B., & O'Dwyer, P. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3037 · Cited by 50
The RET proto-oncogene: a potential target for molecular cancer therapy
Pützer, B. M., & Drosten, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.06.002 · Cited by 47
Receptor-Targeted Cancer Therapy
Richter, M., & Zhang, H. (2005) · DNA and Cell Biology · doi:10.1089/dna.2005.24.271 · Cited by 40
Resistance to tyrosine kinase inhibitors: Calling on extra forces
Cools, J., Maertens, C., & Marynen, P. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.005 · Cited by 40
Johnston, S. R. D. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00992 · Cited by 37
Scientific Basis of Cancer Chemotherapy
(1969) · Springer eBooks · doi:10.1007/978-3-642-88147-3 · Cited by 28
Hensel, M., Rieker, R. J., Libicher, M., Lehnert, T., Penzel, R., Mechtersheimer, G., & Egerer, G. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-003-0945-5 · Cited by 27
Lee, C. P., Attard, G., Poupard, L., Nathan, P., Bono, J. S. D., Temple, G., Štefanič, M., Padhani, A. R., Judson, I. R., & Rustin, G. J. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3054 · Cited by 15
(2001) · PubMed
Cited by
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Cell death-based treatment of lung adenocarcinoma
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0063-y · Cited by 768
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Self-citation
Metadata
- Authors
- FAIVRE, S., DJELLOUL, S., & RAYMOND, E.
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2006-08
- Volume
- 33
- Issue
- 4
- Pages
- 407-420
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W2079384315
- Cited by
- 264
- References
- 108
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.